Stockholm-based Elekta secures €100 million EIB loan to advance cancer and neurological treatments

Stockholm-based HealthTech firm Elekta has obtained a loan of up to €100 million from the European Investment Bank (EIB) to further develop cancer and neurological treatments. This financing is part of the EIB Group's TechEU programme, aimed at bolstering European investment in strategic technologies and innovation, and aligns with EU goals related to health research, competitiveness, and advanced medical technology.

Karl Nehammer, Vice-President of the EIB, stated, "Europe has world-leading medical-technology companies and we need to ensure they can continue investing and innovating here. This financing will support the next generation of cancer and neurological treatments."

The EIB loan will cover approximately half of a €200 million research program planned by Elekta between 2026 and 2029, with most of the work set to take place in Sweden and the Netherlands. In 2025 alone, the EIB Group provided €100 billion in new financing and advisory support for over 870 projects related to climate action, digitalisation, security and defence, and social infrastructure.

Elekta, founded in 1972 and listed on Nasdaq Stockholm, develops precision radiation medicine for various cancers and neurological disorders. The company's technology, which utilizes adaptive radiotherapy, precision treatment delivery, and integrated clinical workflows, treats more than 2 million patients annually across 120 markets worldwide. With around 4,000 employees, Elekta is committed to improving treatment accuracy and efficiency while enhancing patient care and healthcare provider experience.